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Mood disorders are relatively common serious human diseases for which there is often no ideal pharmacotherapy. Basic characteristic 
of these diseases is affective disorder shifting the mood of the patient to depression (together with anxiety or not) or towards to 
euphoria. Available drugs are usually divided into two groups – mood stabilizers, which are used primarily to treat bipolar disorder, 
and antidepressants for the treatment of unipolar depression. Lithium is still recommended as the first choice for dealing with bipolar 
disorder. Despite abundant clinical use of mood stabilizing drugs, important questions regarding their mechanism of action remain open. 
In this paper we present the brief review of rather diversified hypotheses and ideas about mechanisms of genesis of mood disorders 
and lithium interferences with these pathological states. New data derived from the high-resolution crystallographic studies of allosteric, 
Na+-binding sites present in G protein coupled receptors are given together with data indicating the similarity between lithium and 
magnesium cations. In this context, similarities and dissimilarities between the useful “poison” with narrow therapeutic window (Li+) 
and the bivalent cation acting like cofactor of more than 300 enzymatic reactions (Mg2+) are pointed out together with results indicating 
enhanced activity of trimeric G proteins in bipolar disorder.
Key words: bipolar disorder, lithium, sodium, magnesium, G protein coupled receptors, Na+-allosteric site.
INTRODUCTION
Mood disorders (affective disorders), including 
bipolar disorder and (unipolar) depression, are relatively 
common serious human diseases for which there is often 
no ideal pharmacotherapy. These diseases hold profound 
implications not only for the patients but also for their family 
members and the whole society. Basic characteristic of these 
types of diseases is affective disorder shifting the mood of 
the patient to depression (together with anxiety or not) or 
towards to euphoria. There are several treatment options 
for mood disorders. Available drugs are usually divided into 
two groups – mood stabilizers, which are used primarily to 
treat bipolar disorder, and antidepressants for the treatment 
of unipolar depression (Schloesser et al. 2012). Despite 
abundant clinical use of mood stabilizing drugs, important 
questions regarding their mechanism of action remain open.
Mood disorders are often difficult to diagnose. More 
than half of patients who turn to their general practitioners 
for depressive disorders are wrongly diagnosed (Avissar 
and Schreiber 2002). There is a huge gap between progress 
in the pharmacotherapy of these diseases and the current 
lack of objective biological tests for diagnosis (Avissar and 
Schreiber 2002). High risk of committing suicide in patients 
with mood disorders is a reason for finding clinically 
applicable methods for measuring biochemical changes 
that accompany these disorders. Such a method could 
facilitate the implementation of appropriate interventions.
Bipolar disorder is an episodic mood disorder 
characterized by two or more phases, during which mood 
and activity level of a patient are significantly disrupted. 
Under certain circumstances the bipolar patient is in elated 
or irritable mood or both and has increased activity (mania 
or hypomania – symptoms are less severe or less protracted 
than are those of mania), another time the patient is in low 
mood and has related symptoms such as loss of pleasure 
and reduced activity (depression). So, during this disease 
occur recurrent mood swings.
Bipolar disorder is a serious mood disease with 
a worldwide prevalence of 1–5% of the population (Avissar 
and Schreiber 2002, Schloesser et al. 2012, Amihaesei 
2014, Can et al. 2014) and is an example of a psychiatric 
disorder that is very difficult to accurately diagnose 
(Singh and Rajput 2006, Phillips and Kupfer 2013). Genetic 
predisposition is one of the highest among psychiatric 
disorders. Heritability index is 0.85 (McGuffin et al. 2003). 
The risk of suicide is between 6% and 10%, i.e. 10 times © 
20
16
 b
y A
ct
a N
eu
ro
bi
olo
gi
ae
 Ex
pe
rim
en
ta
lis
Correspondence should be addressed to M. Vosahlikova  
Email: miroslava.vosahlikova@fgu.cas.cz
Received 10 November 2015, accepted 12 February 2016
Review
Acta Neurobiol Exp 2016, 76: 1–19
1_702_Vosahilkova_v4.indd   1 13/04/16   20:00
2  M. Vosahlikova and P. Svoboda Acta Neurobiol Exp 2016, 76: 1–19
higher than in the general population (Cipriani et al. 2013) 
and at about 10–20% of bipolar disorder patients commit 
suicide in the course of this disease (Rihmer and Kiss 
2002, Gonzalez-Maeso and Meana 2006, Rybakowski 2013). 
Adequate treatment should allow the long-term remission 
and good functioning in majority of patients (Rybakowski 
2013), however, the evidence regarding the efficacy of 
standard medical procedures, especially antidepressants, 
remain limited and inconsistent (Vazquez et al. 2013).
Mood stabilizers play the most important role in the long-
term treatment of bipolar disorder. If some drug stabilizes 
mood symptoms associated with bipolar disorder, without 
affecting the others, the substance can be considered as a 
mood stabilizer (Baldessarini 2013). Mood stabilizer should 
ideally be effective in treatment of both poles (manic and 
depressive) of the acute symptoms of bipolar disorder equally 
and also prevent these symptoms (Bauer and Mitchner 
2004). Current mood stabilizers, however, have mostly 
efficiency at one pole and lower efficiency on the other 
(Rybakowski 2013). Mood stabilizers used for treatment 
of bipolar disorder include lithium, anticonvulsants 
(valproate, carbamazepine, lamotrigine), antipsychotics 
(e.g. chlorpromazine, olanzapine, quetiapine etc.), and 
antidepressants (e.g. imipramine, iproniazid, meprobamate 
etc.) (Baldessarini 2013). Among mood stabilizers, lithium 
is regarded as unique therapeutic agent and the only true 
mood stabilizer in the management of bipolar disorder. It 
has held the pole position for more than half a century and 
is especially effective in treating acute mania and providing 
long-term prophylaxis. Its profound anti-suicidal properties 
further justify its use in bipolar disorder (Malhi et al. 2013).
LITHIUM
While the first discovery of therapeutic potential of 
lithium in bipolar disorder treatment in the late 40s of 
the 20th century is generally attributed to an Australian 
psychiatrist John Cade, it should be recognized that a 
number of considerations on the use of lithium salts in 
psychiatric conditions preceded his findings (Mitchell and 
Hadzi-Pavlovic 2000, Can et al. 2014, Oruch et al. 2014). It had 
been assumed, that many diseases, including psychological 
diseases, are the results of an imbalance of uric acid. In 
the 19th century lithium salts were used in the treatment 
of gout for their ability to dissolve uric acid crystals in 
vitro and later Lange and Hammond used independently 
lithium to treat mania (Mitchell and Hadzi-Pavlovic 2000, 
Baldessarini 2013, Can et al. 2014, Oruch et al. 2014). The 
final acceptation of lithium as an active substance for the 
treatment of bipolar disorder was significantly contributed 
by research of the Danish psychiatrist Mogens Schou and 
his colleague Poul Christian Baastrup (Schou et al. 1954, 
Baastrup and Schou 1967, Baastrup et al. 1970, Schou 1999).
Even though there is a decline in the use of lithium in 
the last few years, it is still recommended as the first choice 
for dealing with bipolar disorder according to all of the 
current medical handbooks (Grandjean and Aubry 2009b). 
Lithium is a typical mood stabilizer and has in this group 
of drugs a unique position. It has both the antimanic and 
extraordinary antidepressant activity; the antimanic effect 
being more pronounced than antidepressant. Unlike mood 
stabilizers that were originally indicated in the treatment 
of other diseases (anticonvulsants for treating epilepsy and 
antidepressants to treat schizophrenia), lithium is almost 
entirely effective in the treatment of mood disorders 
(Can et al. 2014). Moreover, there is evidence that lithium 
reduces the high risk of suicide in patients with bipolar 
disorder (Grandjean and Aubry 2009b, Kovacsics et al. 2009, 
Manchia et al. 2013). Only a subset of patients, however, 
shows therapeutic response to lithium (Can et al. 2014). 
Individual response to lithium is variable and has been 
reported as a heritable trait (Hou et al. 2016).
Clinical studies have also shown that lithium causes 
granulocytosis and lymphopenia while it enhances 
immunological activities of monocytes and lymphocytes. 
Lithium was used to treat granulocytopenia resulting from 
radiation and chemotherapy, to boost immunoglobulins 
after vaccination, and to enhance natural killer activity 
(Young 2009). Lithium acts through multiple pathways to 
inhibit glycogen synthase kinase 3β (GSK-3β). This enzyme 
phosphorylates and inhibits nuclear factors that turn on 
cell growth and protection programs, including the nuclear 
factor of activated T cells (NFAT) and WNT/β-catenin (WNT 
– wingless-type mouse mammary tumor virus integration 
site family). In animals, lithium upregulates neurotrophins, 
including brain-derived neurotrophic factor (BDNF), nerve 
growth factor, neurotrophin-3 (NT3), as well as receptors 
to these growth factors in brain. Lithium also stimulates 
proliferation of stem cells, including bone marrow and 
neural stem cells in the subventricular zone, striatum and 
forebrain. The stimulation of endogenous neural stem 
cells may explain why lithium increases brain cell density 
and volume in patients with bipolar disorder. Lithium 
also increases brain concentrations of the neuronal 
markers n-acetyl-aspartate and myo-inositol. Lithium also 
remarkably protects neurons against glutamate, seizures, 
and apoptosis due to a wide variety of neurotoxins. Lithium 
has been also reported to be beneficial in animal models 
of brain injury, stroke, Alzheimer’s, Huntington’s, and 
Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), 
spinal cord injury, and other conditions (Young 2009).
At neuronal level, lithium reduces excitatory 
(dopamine and glutamate) but increases inhibitory (GABA 
– γ-aminobutyric acid) neurotransmission; however, these 
broad effects are underpinned by complex neurotransmitter 
systems that strive to achieve homeostasis by way of 
compensatory changes. For example, at an intracellular 
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and molecular level, lithium targets second-messenger 
systems that further modulate neurotransmission. For 
instance, the effects of lithium on the adenylyl cyclase and 
phosphoinositide pathways, as well as protein kinase C, may 
serve to dampen excessive excitatory neurotransmission. 
In addition to these many putative mechanisms, it has also 
been proposed that the neuroprotective effects of lithium 
are keys to its therapeutic actions. In this regard, lithium 
has been shown to reduce the oxidative stress that occurs 
with multiple episodes of mania and depression. Further, 
it increases protective proteins such as brain-derived 
neurotrophic factor and B-cell lymphoma 2, and reduces 
apoptotic processes through inhibition of glycogen 
synthase kinase 3 and autophagy. Overall, it is clear that 
the processes which underpin the therapeutic actions 
of lithium are sophisticated and most likely interrelated 
(Malhi et al. 2013).
Lithium transport across cell membrane
Lithium can be transported across the plasma (cell) 
membrane in several different ways (Reiser and Duhm 
1982). The entry of lithium into the cell proceeds mainly 
as passive transport via voltage-gated sodium channels 
(Na+v). The Na+-Li+ counter-transport displaces lithium 
back from the cell interior to the extracellular space. In 
cells with physiological concentrations of Na+ and K+, the 
ouabain-dependent Na+/K+ pump mediates intake of Li+, 
but is unable to release Li+ back into extracellular space. 
Consequently, the intracellular concentration of lithium 
is increased in conditions of hyper-excitation of neuronal 
membrane (el-Mallakh and Wyatt 1995).
Li+ enters the cells primarily through Na+v, because 
permeability of these channels for both cations is roughly 
equal (el-Mallakh 2004). Influx of Li+ in this way is stimulated 
by veratridine and scorpion toxin; stimulation is blocked 
by tetrodotoxin. The pore diameter of Na+v is sufficiently 
limited, so that the small ions such as Na+ and Li+ can pass 
through the channel easily, but the transport of larger 
ions such as K+ ions is significantly impeded. This allows 
Li+ pass quickly through Na+v during neurotransmission. 
Consequently, the exogenously added Li+ can spread 
rapidly throughout the body and enter neurons as well as 
skeletal and smooth muscle cells. It should be mentioned 
in this respect that ionic radius of non-hydrated lithium 
(0.68 Å) is smaller than of sodium (0.95 Å) and very close to 
the size of non-hydrated magnesium (0.65 Å) (Komoroski 
and Pearce 2008). It is therefore possible that the range 
of Li+ effects proceeding in the cell interior and plasma 
membrane is based on competition with sodium and 
magnesium ions bound to variety of enzymes, transport 
and regulatory protein molecules. In this way, the overall 
cell metabolism (Young 2009) and synthesis and release of 
neurotransmitters across the plasma membrane may be 
altered (Komoroski and Pearce 2008).
The lithium efflux occurs mainly through an electrically 
neutral pump called Na+-Li+ counter-transporter 
(el-Mallakh 2004), which in vivo exchanges sodium for 
sodium, but also accepts lithium (Vaccaro et al. 2005). 
Lithium ions may replace sodium ions in this system and 
be transported via this carrier across the cell membrane 
in both directions (Mallinger et al. 1997). This transport 
route is not sensitive to ouabain or external K+, is active 
in cell membranes of various types of tissues (Mallinger 
et al. 1997) and plays an important role in the biological 
disposition of clinically dosed lithium salts as during the 
lithium treatment, the Na+-Na+ exchanger is inhibited and 
the rate of lithium efflux decreased (Mallinger et al. 1997, 
Koltsova et al. 2011). The out-ward oriented movement of 
ions through Na+-Li+ counter-transport is (in the course of 
lithium-based therapy) decreased because of the reduced 
affinity of intracellular binding sites of this transporter 
for Li+ (Mallinger et al. 1997). Therefore, the regulation of 
the speed of clearance of lithium from the cell contributes 
significantly to the therapeutic effects of lithium in the 
course of treatment of variety of psychiatric disorders 
(Mallinger et al. 1997, Koltsova et al. 2011).
Although the pathogenesis of bipolar illness is 
not yet fully understood, the several clearly defined 
pathophysiological abnormalities arising in acute, manic 
phase of the disease were described. One of the oldest and 
most consistent findings is the modified ion homeostasis: 
bipolar patients have increased intracellular sodium 
concentration, increased free intracellular calcium 
level and reduced activity of sodium plus potassium 
activated, ouabain-dependent adenosinetriphosphatase, 
Na+/K+-ATPase, in manic phase of bipolar disease (el-Mallakh 
and Wyatt 1995, el-Mallakh 2004). In manic phase of 
bipolar disease (mania) lithium ions enter the neurons in 
amounts exceeding capacity of its efflux and were found 
to be preferentially accumulated within the dendritic 
spines (el-Mallakh 2004). The benefaction by lithium was 
interpreted as extrusion of intracellular sodium thereby 
reducing (normalizing) intracellular sodium concentration 
([Na+]i) and renewing the sodium electrochemical gradient 
across plasma membrane and resting membrane potential 
(el-Mallakh 2004).
Lithium affects a number of biochemical processes by 
competing with endogenous cations and, because most of 
these processes occur inside the cell, it is often said that the 
lithium mediates its therapeutic effects in the intracellular 
space of the brain neurons (Komoroski and Pearce 2008, 
Komoroski et al. 2013). Intracellular concentration of 
lithium is significantly lower than its concentration in 
the blood or extracellular fluid. This finding is important 
for models which have been proposed for its mechanism 
of action, since such a models must be able to explain 
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the effects of lithium at its intracellular concentration. 
However, in some in vivo cellular systems the very low 
intracellular concentrations of lithium were found (<10% 
of the extracellular) together with highly limited access of 
lithium to the intracellular space. Therefore, it has been 
also suggested that the mechanism of action of lithium 
may be partly based on interaction with external surface of 
plasma membrane (Birch 1994, Thellier et al. 1997).
Mechanism of lithium action in brain
The chemically simple substances such as lithium salts, 
which have a very important position in the treatment of 
bipolar disorder, do not have some clearly defined biological 
function in the body (Aral and Vecchio-Sadus 2008). 
Despite the abundant clinical use of lithium, the molecular 
mechanism of action by which this small monovalent ion 
exerts its therapeutic effects, remains still not elucidated. 
However, among many different effects of lithium salts 
which have been reported in the up to date literature 
(Odagaki et al. 1997, Minadeo et al. 2001, Srinivasan et al. 
2004, Gonzalez-Maeso and Meana 2006, Gershon et al. 2009, 
Freland and Beaulieu 2012, Malhi et al. 2013, Keltner and 
Steele 2015), some represent the well-grounded theoretical 
basis for explanation of therapeutically significant 
reactions proceeding under in vivo conditions. All the 
mechanisms of lithium action discussed in this review are 
introduced in Fig. 1.
The major models for bipolar disorders were originally 
divided into two main categories: dendritic or postsynaptic 
models that focused on the function of trimeric G proteins 
and the secondary messengers such as Ca2+ and IP3 
(1,3,5-innositol trisphosphate); the axonal or presynaptic 
models that focused on membrane pumps and ion fluxes. 
The “sodium pump” hypothesis proposed that the decrease 
of activity of Na+/K+-ATPase may produce both mania and 
bipolar depression (el-Mallakh and Wyatt 1995). After 
30 years of research and collection of experimental data from 
more clearly defined groups of bipolar patients which were 
distinguished from those suffering from other psychiatric 
disorders, the more refined hypotheses were formulated: 
lithium replaces sodium and alters intracellular calcium 
concentration; lithium inhibits the release and facilitates 
the uptake of primary messengers noradrenaline, serotonin 
and dopamine; lithium regulates Na+/K+-ATPase pump; 
lithium stabilizes the system of secondary messengers and 
regulates cAMP- and Ca2+-dependent intracellular signaling 
cascades (Keltner and Steele 2015).
There are no doubts that abnormal mood states 
observed in bipolar disorder are associated with an increase 
in the concentration of intracellular sodium and calcium. It 
is therefore assumed that these changes may be causatively 
linked to the pathogenesis of this disease (el-Mallakh 2004). 
Particularly acute manic patients have increased sodium 
retention, increased overall body and intracellular sodium 
concentrations, increased intracellular free calcium 
concentration and reduced activity of Na+/K+-ATPase 
(el-Mallakh and Wyatt 1995). Curiously, reduction of 
Na+/K+-ATPase pump activity may be responsible for both 
phases of disease – mania and depression. Mania would 
be associated with an increase of [Ca2+]i in pre-synaptic 
compartment, increased fusion of neurotransmitter 
containing vesicles with plasma membrane and increased 
stimulation of postsynaptic membrane (Ullrich et al. 
1980, 1982, el-Mallakh 1983a, el-Mallakh and Wyatt 1995). 
Fig. 1. Mechanisms of lithium action discussed in this review.
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Depression would be consequently caused, when 
Na+/K+-ATPase activity is still decreased, by increased 
intracellular concentration of calcium, hydrolysis of PIP2 
and increased production of IP3. In this way, the post-
synaptic depolarization would proceed even in the absence 
of first messengers and lithium was suggested to be able to 
block this false, agonist-independent signaling (el-Mallakh 
and Li 1993). In support of this hypothesis, lithium was 
found to accumulate mainly in active neurons (el-Mallakh 
1983b). As mentioned above, intracellular accumulation of 
lithium results in replacement of sodium, which in turn 
lowers [Ca2+]i. Decreased [Ca2+]i normalizes the activity of 
neurons in both mania and depression.
When screening the other literature data, it may 
be generally said that lithium competes with sodium, 
potassium, calcium and magnesium in the nerve tissue. 
Impulse conduction is primarily altered by lithium ions 
attached to a range of different types of “binding sites” 
present in CNS. As the Li+ ion radius is similar to the ionic 
radius of magnesium ions, Li+ has the ability to compete 
with Mg2+, which is a cofactor of wide variety of magnesium-
-dependent enzymes regulating the cell metabolism (Can 
et al. 2014). At therapeutic concentrations, lithium inhibits 
intracellular enzymes regulating secondary messenger 
levels: cAMP-dependent phosphodiesterases, inositol 
bisphosphate nucleotidases and inositol monophosphatases 
(Freland and Beaulieu 2012, Can et al. 2014).
Pharmacological research of affective disorders was 
also oriented to GPCRs (G protein coupled receptors) and, 
subsequently, to other membrane proteins regulating 
both the initial and following steps of GPCR-initiated 
signaling cascades. This area of research was most recently 
and thoroughly reviewed by Can and others (2014). 
Administration of lithium to rats (0.2% in food for 10 days) 
was found to inhibit specific [3H]5-hydroxytryptamine 
(5-HT) binding and degree of inhibition of forskoline-
stimulated adenylyl cyclase by 5-HT in hippocampal 
membranes. It also reduced [3H]ketanserine binding and 
5-HT-stimulated IP3 production (Newman et al. 1990).
Alterations associated with depressive disorders of 
α2A-adrenergic (Callado et al. 1998, Gonzalez-Maeso et al. 
2002, Sequeira et al. 2004), 5-HT1A serotonin (Sargent et al. 
2000, Arango et al. 2001, Hsiung et al. 2003, Bhagwagar et 
al. 2004), µ-opioid (Gabilondo et al. 1995, Gross-Isseroff et 
al. 1998, Escriba et al. 2004) and CB1 cannabinoid (Hungund 
et al. 2004) receptors, both in terms of density and their 
functionality, were thoroughly tested and documented in 
numerous reports.
Mechanisms involving the interference of lithium with 
GPCR-G protein coupling were also analyzed rather early 
and the efforts to delineate the role of GPCR and G proteins 
in genesis and pharmacological treatment of bipolar 
disease continue since the present time (Avissar and 
Schreiber 2002). In 1988 it was first reported that trimeric 
G proteins are involved in basic biochemical mechanism of 
therapeutic action of lithium (Avissar et al. 1988, Avissar 
and Schreiber 2002). Lithium at therapeutically efficacious 
concentrations completely blocked both adrenergic and 
cholinergic stimulation of high-affinity binding of non-
hydrolysable analog of GTP ([35S]GTPγS – guanosine-5’-
-O-[γ-35S]-triphosphate) to membranes prepared from rat 
cerebral cortex under both in vitro and ex vivo conditions. 
The same lithium treatment abolished guanine-nucleotides 
modulation of agonist binding (Avissar et al. 1988).
The coupling of both muscarinic-cholinergic receptors 
and β-adrenergic receptors to pertussis toxin-sensitive 
G proteins or cholera toxin-sensitive G proteins was 
compared in mononuclear leukocyte (MNL) membrane 
preparations isolated from untreated manic patients, 
lithium-treated euthymic bipolar patients and healthy 
volunteers (Schreiber et al. 1991). Hyperactive function 
of G proteins was detected in untreated manic patients. 
Both isoproterenol-induced and carbamylcholine-induced 
increases in Gpp(NH)p (5’-guanylyl imidodiphosphate) 
binding capacity were two-fold to three-fold higher than the 
increases observed in healthy volunteers. On the other hand, 
lithium-treated euthymic bipolar patients showed G protein 
responses to agonist activation that were no different from 
the healthy volunteers. An altered G protein function 
was therefore considered to have pathophysiological 
importance in genesis of bipolar disorder. Hyper-function 
of G proteins, changes in activity of PKC and PKA (protein 
kinase C and A) and cellular phosphorylation state in 
CNS were suggested to create an unstable “catastrophic” 
dynamic (oscillatory) system characteristic of a manic or 
depressive state. Lithium treatment attenuates G protein 
function and damps the oscillatory system to yield a stable 
state (Schreiber et al. 1991).
Lithium and glutamate signaling cascades
The serotonin-, dopamine- and noradrenaline-initiated 
signaling cascades have received the greatest attention in 
neurobiological studies of mood disorders as the majority of 
antidepressants exert their initial effects by increasing the 
intrasynaptic levels of serotonin and/or noradrenaline (Can 
et al. 2014). However, the meaningful improvement of severe 
depressive symptoms (major depressive disorder and bipolar 
disorder) emerges only after several weeks of antidepressant 
therapy, suggesting that downstream neural adaptations 
rather than the elevation in synaptic monoamine levels 
itself are responsible for their therapeutic effects (Drevets 
2001, Dunlop and Nemeroff 2007, Sanacora et al. 2008).
The search for the primary cause of mood disorders was 
therefore also oriented to analysis of mechanism of action 
of the major mediator of excitatory synaptic transmission 
in mammalian brain – glutamate (Orrego and Villanueva 
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1993). Under normal conditions, glutamate has a prominent 
role in synaptic plasticity, learning and memory, but 
under pathophysiological conditions it is known to be the 
powerful neuronal excitotoxin. In patients with bipolar 
disorder, glutamate concentrations were significantly 
increased in anterior cingulate cortex (ACC) and decreased 
in hippocampus (Ehrlich et al. 2015).
Patients with bipolar disorder are generally treated 
with a class of medicines known as mood stabilizers. Mood 
stabilizers have antimanic effects, exert prophylactic 
effects in preventing recurrent manic or depressive 
episodes and also exhibit antidepressant properties. The 
prototypical agent of this class of therapeutics is lithium. 
In view of the evidence that excessive synaptic glutamate 
may contribute to neuronal atrophy and degradation, 
it is noteworthy that chronic treatment with lithium 
has been shown to upregulate synaptosomal uptake 
of glutamate (Hokin et al. 1996, Bowden et al. 2000). 
Furthermore, chronic treatment with therapeutically 
relevant concentrations of lithium in cultured rat 
cerebellar, cortical and hippocampal neurons protected 
these cells against glutamate-induced excitotoxicity. 
The investigators reported that the protection could be 
attributed to inhibition of NMDA (N-methyl-D-aspartate) 
– receptor-mediated Ca2+ influx (Nonaka et al. 1998, 
Hashimoto et al. 2002).
This is plausible explanation indeed as NMDA-
receptors are blocked under resting conditions by 
intracellular magnesium cations [intracellular magnesium 
concentrations range from 5 to 20 mM; 1–5% is ionized, 
the remainder is bound to proteins, negatively charged 
molecules and ATP (Jahnen-Dechent and Ketteler 
2012)] and, once the surrounding plasma membrane 
area is depolarized by opening of AMPA (α-amino-3-
-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, 
NMDA-receptors are activated by combined binding of two 
glutamate and two glycine molecules. NMDA-receptors 
activation serves as a functional marker of converging 
excitatory inputs, produces excitation over long period of 
time and an increased AMPA/NMDA throughput in critical 
neuronal circuits was suggested to represent the critical 
step in antidepressant action. Evidence for alteration of 
NMDA- and AMPA/kainate-receptors function has been 
intensively documented (Zarate et al. 2002, 2003, Kugaya 
and Sanacora 2005, Sanacora et al. 2008, Gray and McEwen 
2013, Malhi et al. 2013).
Lithium and γ-aminobutyric acid (GABA) signaling 
cascades
GABA is the main inhibitory neurotransmitter in 
mammalian brain (Bowery et al. 1984, 1987, Sakaba 
and Neher 2003, Padgett and Slesinger 2010, Pinard et 
al. 2010) which plays a crucial role in modulating both 
dopamine and glutamate neurotransmission and hence it 
is also thought to play a key role in mood stabilization 
(Brambilla et al. 2003). Patients with mood disorders, in 
particular bipolar disorder, have diminished GABA-ergic 
neurotransmission (Kato 2008, Ng et al. 2009, Ghasemi 
and Dehpour 2011). Low GABA levels result in an increase 
in excitatory neurotransmission that leads to excitatory 
toxicity, and in turn causes apoptosis and cell loss 
(Rajkowska et al. 2001, Rajkowska 2002). In this context, 
lithium promotes the release of neuroprotective proteins 
and decreases the levels of pro-apoptotic proteins 
(Chuang et al. 2002). Lithium increases the level of GABA 
in the plasma and cerebrospinal fluid of humans as that 
of rats (Ahluwalia et al. 1981, Vargas et al. 1998, Brunello 
and Tascedda 2003). Interestingly, an increase in GABA in 
response to lithium reduces the level of glutamate, and 
this downregulates the NMDA-receptor (Ghasemi and 
Dehpour 2011).
Lithium, magnesium and trimeric G proteins
The average size of non-hydrated lithium cation 
(0.68 Å) is very close to the size of magnesium cation in 
crystal (0.65 Å). In aqueous solution, ionic radii of four- 
and six- water coordinate Li+ is 0.60 and 0.79 Å, respectively 
(Mahler and Persson 2012). In aqueous solutions, Li+ is more 
similar to Mg2+ than to Na+ and K+. When considering this 
similarity, one should bear in mind that ATP metabolism 
as well as normal neurological function and release 
of neurotransmitters are all magnesium dependent 
(Jahnen-Dechent and Ketteler 2012). Magnesium binds 
water molecules much tighter than calcium, potassium 
and sodium. Thus, the hydrated magnesium cation is 
hard to dehydrate. Its radius is ~400 times larger than 
its dehydrated radius. The difference between the 
hydrated and the dehydrated state is much larger than 
in sodium (~25-fold), calcium (~25-fold) or potassium 
(4-fold). Magnesium is surrounded by two hydration 
shells, whereas calcium has just one layer. If these two 
divalent cations need to fit into a structure of an enzyme 
or pore of ionic channel/transporter membrane protein, 
calcium will simply shed away its hydration shell and 
its dehydrated form will fit in. Magnesium, on the other 
hand, has to lose two layers of water molecules which is 
highly energy consuming.
It has been proposed that Li+, a metal ion with an ionic 
radius similar to that of Mg2+ (Malarkey et al. 2008), can 
compete with Mg2+ for low affinity Mg2+-binding sites in 
trimeric Gα subunits (Avissar et al. 1988, 1991, Mota de 
Freitas et al. 2006). Several of the seminal Gi1α protein 
crystallographic experiments that showed one Mg2+-
-binding site were conducted in the presence of very 
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high (up to 2 M) Li+ concentrations (Coleman et al. 1994a, 
1994b, Coleman and Sprang 1998), or were modeled 
on structures obtained in the presence of very high Li+ 
concentrations (Sunahara et al. 1997, Tesmer et al. 1997). 
Hence, it is plausible that the Mg2+ at the low affinity 
Mg2+-binding site was displaced by Li+ and therefore not 
observed in the previously reported X-ray structures. 
Interestingly, in the only G protein X-ray structural study 
where two Mg2+-binding sites were observed (Nicely et al. 
2004), crystallization was conducted with polyethylene 
glycol rather than in high salt conditions. When 
another enzyme that has been shown to be susceptible 
to Li+/Mg2+ competition at Mg2+-binding sites, inositol 
monophosphatase (IMPase), was originally crystallized 
in the presence of high lithium sulfate concentrations 
(2.0 M), only one Mg2+-binding site was observed (Bone et 
al. 1992, 1994); however, a recent crystallographic study 
of IMPase that used no Li+ in the crystallization medium 
showed the presence of not one, but three Mg2+-binding 
sites in the protein (Gill et al. 2005) giving further credence 
to the idea that weakly bound Mg2+ can be displaced by Li+ 
in biomolecules.
Magnesium cations have a profound stimulatory effect 
on the interaction of many G protein coupled receptors 
with their agonists. The list of receptors that fall into this 
category includes β-adrenergic receptor (β-AR) (Bird and 
Maguire 1978, Williams et al. 1978), α2-adrenergic receptor 
(α2-AR) (Tsai and Lefkowitz 1978, 1979, Glossmann and 
Presek 1979), muscarinic acetylcholine receptor (mACh-R) 
(Wei and Sulakhe 1980, Hilf et al. 1989) and receptors for 
PGE1 (prostaglandin E1) (Williams et al. 1978), opioids 
(Pasternak et al. 1975), dopamine (Sibley and Creese 1983) 
and chemotactic formyl peptide receptors (Gierschik et al. 
1989, 1991). In most cases, the major effect of magnesium 
cations was an increase in receptor affinity for the agonist 
[β-AR (Bird and Maguire 1978, Williams et al. 1978) and 
α2-AR (Tsai and Lefkowitz 1978)], although an increase 
in the number of binding sites was also noticed [mACh-R 
(Glossmann and Presek 1979)].
Therefore, the effect of magnesium cations is 
diametrically opposite to the effect of guanine nucleotides, 
which are well known to reduce agonist affinity of all 
GPCRs. As the latter effect is due to a nucleotide-dependent 
functional and physical uncoupling of the receptor from 
G protein, it has been suggested that magnesium cations 
enhance agonist binding by stabilization of ternary, high-
affinity complex H-R-G (complex hormone-receptor-G 
protein) which is necessary intermediate for hormonal 
stimulation of effector enzymes as well as guanine 
nucleotide-dependent transition of receptor from the 
high to low-affinity state (Bird and Maguire 1978, Tsai and 
Lefkowitz 1978, 1979,  Williams et al. 1978). It was suggested 
that lithium interaction with G proteins may proceed as 
direct competition with magnesium ions bound to the 
low-affinity Mg2+-sites in Gα subunits (Malarkey et al. 
2008). Mg2+-binding is known to be essential for agonist-
stimulated GDP-GTP exchange reaction proceeding in 
guanine-nucleotide binding domain of Gα subunits, namely, 
for the fast change of Gα-GTP conformation (Gilman 
1987, Higashijima et al. 1987a, 1987b, 1987c). Activation 
of G proteins by guanine nucleotides changes the protein 
conformation. Concomitant with this structural change is 
an increase in the intensity of fluorescence of tryptophan 
residues. Both GTPγS and GTP can cause this change, 
suggesting that a similar alteration in protein structure is 
caused by the different nucleotides. When GTP is added to 
GDP-containing Go, there is a slow increase in the intensity 
of tryptophan fluorescence as GDP dissociates and GTP 
then binds. After GDP has been replaced with GTP, the 
addition of Mg2+ causes a rapid increase in fluorescence 
intensity, reflecting the formation of Goα-GTP-Mg2+. Unlike 
the complex formed in the presence of GTPγS, the GTP 
containing form of the protein is transient, because GTP is 
hydrolyzed to GDP and Pi in the presence of Mg2+.
Further down-stream, lithium was found to decrease 
activity of numerous signaling proteins which are 
primarily regulated by G proteins. (Avissar and Schreiber 
2006, Gonzalez-Maeso and Meana 2006, Can et al. 2014). 
Lithium was found to inhibit adenylyl cyclase activity 
(Avissar et al. 1988, Mork and Geisler 1989, Newman et 
al. 1990, Minadeo et al. 2001, Srinivasan et al. 2004), turn-
over of neurotransmitter-stimulated phosphatidylinositol 
metabolism (Jope and Williams 1994) and activity of 
inositol-1-monophosphatase (Wang and Friedman 1999). 
As c-AMP- and IP3-dependent cascades are regulated by 
different G protein families (Gs, Gi, Go, Gq/G11), the effect of 
chronic lithium on functional coupling between serotonin 
(5-HT) receptors and G proteins was investigated in details 
(Wang and Friedman 1999). Incubation of rat cortical 
membranes with 5-HT increased [35S]GTPγS binding to 
Gsα, Giα, Goα and Gqα proteins. Six weeks but not one week 
of lithium treatment reduced the 5-HT-stimulated [35S]
GTPγS binding to Gsα, Giα and Goα by 75–85%, whereas 5-HT 
stimulated [35S]GTPγS binding to Gqα was decreased by 
38%. No changes of Gα protein levels were noted in lithium 
treated rats. Increases in [35S]GTPγS binding to Gα proteins 
by 5-HT were also inhibited by 0.5–2 mM lithium chloride 
added in vitro to assays mixture. Rubidium and cesium 
did not change 5-HT-stimulated G protein activity. The 
inhibitory effect of lithium on 5-HT-stimulated [35S]GTPγS 
binding to Gsα and Gqα was completely removed by 2.4 mM 
MgCl2; this concentration of MgCl2 competed out the effect 
of lithium on Giα and Goα by 50%. These results indicated 
that lithium interferes with receptor-G protein coupling 
via a Mg2+-dependent mechanism.
Receptor-mediated G protein activation and changes in 
the amount of different Gα subunits were further examined 
in frontal cortical membranes obtained from postmortem 
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brains of bipolar affective disorder subjects and from age-, 
sex-, and postmortem interval-matched controls (Friedman 
and Wang 1996). Stimulation of cortical membranes with 
serotonin, isoproterenol, or carbachol increased [35S]GTPγS 
binding to specific Gα proteins in a receptor-selective 
manner. The abilities of receptor agonists to stimulate the 
binding of [35S]GTPγS to the Gα proteins was enhanced in 
membranes from bipolar brains. Immunoblot analyzes 
showed increases in the levels of both short and long (45 and 
52 kDa) isoforms of Gsα, but no changes in the amounts of 
Giα, Goα, Gzα, Gq/11α or Gβ subunit proteins in membrane or 
cytosol fractions of bipolar brain homogenates. Pertussis 
toxin (PTX)-activated ADP-ribosylations of Giα and Goα were 
enhanced by ≈80% in membranes from bipolar compared 
with control brains. Serotonin-induced, magnesium-
dependent reduction of PTX-mediated ADP-ribosylation 
of Giα and Goα in cortical membranes from bipolar brains 
was greater than that observed in controls, providing 
further evidence for enhanced receptor-G protein coupling 
in bipolar brain membranes. In addition, the amounts 
of Gβ that co-immunoprecipitated with the Gα proteins 
were also elevated in bipolar brains. The data show that 
in bipolar brain membrane there is enhanced receptor-G 
protein coupling and an increase in the trimeric state of 
the G proteins. These changes may contribute to produce 
exaggerated transmembrane signaling and to the alterations 
in affect that characterize bipolar affective disorder.
Over the years, the evidence for “negative”, inhibitory 
effect of lithium on G protein function was strengthened 
and considered to be involved in the pathogenesis as well 
as therapy of mood disorders (Schreiber and Avissar 2007). 
The related hypotheses suggest that G proteins are hyper-
functional in mania and stabilized by lithium treatment 
(Schreiber and Avissar 1991, el-Mallakh and Wyatt 1995). 
Numerous studies have provided evidence for hyper-
function of G proteins and their abnormal quantities 
in postmortem tissues of bipolar patients compared to 
healthy individuals (Schreiber et al. 1991, Young et al. 1991, 
Friedman and Wang 1996, Gonzalez-Maeso and Meana 
2006). Determination of (responding) G protein levels and 
activities was tested as biochemical marker of a given type 
of mental disorder (Avissar and Schreiber 2002).
Genetic background of lithium effects was mostly 
studied in context of heterogeneity and pathological 
mutations of serotonin, dopamine and glutamate receptors 
and of enzymes regulating the synthesis and degradation 
of secondary messengers cAMP and IP3. Genes encoding 
protein kinase C (PKC), Brain Derived Neurotropic Factor 
(BDNF) and glycogen synthase kinase 3β (GSK-3β) were 
recognized in this respect (Rybakowski 2013). In one of the 
latest publications oriented to analysis of candidate genes 
participating in the pathogenesis of mood disorders, OPRK1 
encoding κ1–subtype of opioid receptors was identified 
(Deo et al. 2013).
Opioid receptors and mood disorders
There are a numerous studies that link the endogenous 
opioid system with major psychiatric disorders and suicide 
(Scarr et al. 2012). It has been clearly established that the 
μ-opioid receptors are altered in people with affective 
disorders who died as a result of suicide (Gross-Isseroff 
et al. 1990, Gabilondo et al. 1995). In patients with bipolar 
disorder, the higher levels of specific [3H]DAMGO ([D-Ala2, 
N-MePhe4, Gly-ol]-enkephalin) binding were detected in 
ventral anterior cingulate gyrus (BA24) when compared 
with control patients (Scarr et al. 2012). The role of δ-opioid 
receptor signaling cascade was in turn found to participate 
in the regulation of mood and emotional states, since the 
activation of δ-opioid signaling, according to preclinical 
studies, was reflected in generating of an enormous 
antidepressant-like effects (Jutkiewicz 2006).
It is known, that lithium interacts with opioid system 
and even very low lithium doses can effectively regulate 
opioid transmission (Dehpour et al. 1995, Honar et al. 2004, 
Banafshe et al. 2012). Lithium and morphine have the 
opposite effect on transmembrane signal control systems 
and lithium is able to influence both acute and chronic 
effects of morphine (Dehpour et al. 1995, Honar et al. 2004). 
Lithium may both enhance and attenuate opioid-induced 
antinociception (Dehpour et al. 1994), morphine-induced 
hyperactivity (Carroll and Sharp 1971) and it significantly 
inhibits severity of withdrawal syndrome and development 
of physical dependence (Dehpour et al. 1995) etc.
Chronic administration to lithium stimulates release of 
hypothalamic opioid peptides in the rat brain (Kurumaji et 
al. 1988). This effect was found to be caused by permanent 
decrease in activity of inhibitory opioid auto-receptors 
and G proteins of Gi/Go family (Burns et al. 1990). Blockage 
of these auto-receptors by μ-opioid receptor antagonist 
naloxone causes the release of all three opioid peptides 
– beta-endorphin, met-enkephalin and dynorphin, and 
it does not occur after concomitant administration of 
naloxone together with lithium. Chronic administration 
to lithium has no effect on basal level of opioid peptides, 
but prevents their release induced by naloxone. It was also 
reported that chronic administration of lithium increases 
stress-induced hypoalgesia (Teixeira et al. 1995) and 
increases the expression of μ-opioid receptors in the rat 
brain (de Gandarias et al. 2000).
Lithium and opioid receptors
The interaction of monovalent cations with signaling 
cascades initiated by opioid receptors (OR) was studied 
since the very early days of GPCR-oriented research. The 
stereo-specific binding of OR agonists [3H]dihydromorphine 
and [3H]oxymorphine to brain membranes was found to 
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be inhibited by increasing concentrations of NaCl and 
to a less extent by LiCl (Pert et al. 1973, Pert and Snyder 
1974, Pasternak and Snyder 1975). Other ions, potassium, 
rubidium, and cesium were not effective (Na+ » Li+>K+ 
≈Rb+ ≈Cs+). On the contrary, antagonist binding to OR was 
affected in a positive manner. Binding of the antagonist 
[3H]naloxone was increased, again in the order Na+ » Li+>K+ 
≈Rb+ ≈Cs+. Original data of Pert and Snyder (Pert and 
Snyder 1974) were confirmed and extended by studies on 
membranes prepared from the whole guinea pig brain and 
cerebellum (Paterson et al. 1986).
Later studies of interaction of sodium cations with δ-OR 
using the known amino acid sequence of δ-OR indicated 
that a conserved aspartic acid 95 in the second TM region 
is critical for Na+ regulation of agonist binding (Kong et 
al. 1993). Recent data based on the crystal structure of 
the μ-OR in a complex with the irreversible antagonist 
morphinan (Manglik et al. 2012) and mouse δ-OR with 
the antagonist naltrindol (Granier et al. 2012) at 2.8–3.3 Å 
resolution indicated that these antagonists bind within 
a large solvent-exposed pocket. This extra large “water-
accessible space” of the antagonist binding site of OR is a 
characteristic feature of this type of receptors and differs 
from most other GPCRs including β2-AR (Filizola and 
Devi 2012). The binding pocket of opioid receptors can 
be divided into two distinct regions. The bottom or inner 
part of this pocket is highly conserved among OR whereas 
the upper part (exposed to extracellular aqueous space) 
contains divergent residues that confer subtype selectivity.
The effect of sodium, potassium and lithium on δ-opioid 
receptor ligand binding parameters and coupling with the 
cognate G proteins was also tested in model HEK293 cell 
line stably expressing PTX-insensitive δ-OR-Gi1α (C351I) 
fusion protein (Vosahlikova et al. 2014). Agonist [3H]DADLE 
([D-Ala2, D-Leu5]-enkephalin) binding was decreased in the 
order: Na+»Li+>K+>(+)NMDG (N-methyl-D-glucamine). When 
plotted as a function of increasing NaCl concentrations, 
the binding was best-fitted with a two-phase exponential 
decay considering the two Na+-responsive sites (r2=0.99). 
High-affinity Na+-sites were characterized by Kd =7.9 mM 
and represented 25% of the basal level determined in 
the absence of ions. The remaining 75% represented the 
low-affinity sites (Kd=463 mM). Inhibition of [3H]DADLE 
binding by lithium, potassium, and (+)NMDG proceeded 
in low-affinity manner only. Surprisingly, the affinity/
potency of DADLE-stimulated [35S]GTPγS binding was 
increased in the reverse order: Na+<K+<Li+. This result was 
demonstrated in PTX-treated as well as PTX-untreated 
cells and is therefore valid for both Gi1α (C351I) within the 
δ-OR-Gi1α fusion protein and endogenous G proteins of 
Gi/Go family present in HEK293 cells.
Noticeably, the Kd=7.9 mM of high-affinity sites for 
Na+ determined in δ-OR-Gi1α (C351I) was close to allosteric 
interaction constant KB=13.3 mM determined by Fenalti 
and others (2014). Similarly to our study, these authors 
performed [3H]DADLE binding experiments in media 
containing up to 400 mM NaCl; at 100 mM concentration 
of chloride salts of different ions, the inhibition of [3H]
DADLE binding to BRIL-δ-OR (ΔN/ΔC) [human δ-opioid 
receptor (residues 36–338) with an amino-terminal BRIL 
(apocytochrome b562RIL) fusion protein] was significant 
for sodium only, however, Li+ represented the second most 
effective ion.
As mentioned above, the early studies of rat brain 
homogenates indicated a differential sodium regulation 
of ligand binding to the three major OR subtypes, in spite 
of their high degree of amino acid sequence similarity. 
At physiological concentrations, sodium ions were found 
to decrease the level of binding of agonists, but not 
antagonists to the μ-opioid receptor (μ-OR) (Pert et al. 
1973, Pasternak and Snyder 1975). While similar allosteric 
effects were confirmed for several, albeit not all different 
family A GPCRs (Katritch et al. 2014), the possibility that 
sodium differentially affects the binding of an agonist to 
the three major OR subtypes was also raised, with 65% 
agonist binding inhibition seen in μ-OR and δ-OR, but 
only 20% inhibition observed in κ-opioid receptor (κ-OR) 
(Werling et al. 1986).
Differences in allosteric modulation of individual subtypes 
of OR, µ-, δ- and κ-OR by sodium cations were recently 
characterized by MD (molecular dynamics) simulations with 
the aim to distinguish whether sodium accesses the allosteric 
site (in different OR subtypes) via the similar or different 
pathways (Shang et al. 2014). Rapid sodium permeation 
was observed exclusively from the extracellular milieu, and 
following the similar binding pathways in all three ligand-
free OR systems, notwithstanding extra densities of sodium 
observed near nonconserved residues of κ-OR and δ-OR, 
but not in μ-OR. These differences might be responsible 
for the differential increase in antagonist binding affinity 
of μ-OR by sodium resulting from specific ligand binding 
experiments in transfected cells. On the other hand, sodium 
reduced the level of binding of subtype-specific agonists to 
all OR subtypes.
Lithium – sodium competition for orthosteric and 
allosteric sites of GPCR
In the late 1980s and early 1990s, the concept of 
constitutive GPCR activity was developed. This concept 
assumes that receptors exist in an inactive (R) and an active 
(R*) state and that they isomerize between these two states 
(Lefkowitz et al. 1993). The equilibrium between these 
two states is different for any given receptor, and when 
agonist-independent (constitutive) R to R* isomerization is 
sufficiently high, the measurable basal G protein and effector 
activation is detected (Seifert and Wenzel-Seifert 2002). 
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This basal G protein and effector activity can be reduced 
by inverse agonists that stabilize the R state of receptor 
molecule.
Na+ can effectively reduce constitutive GPCR activity 
and its action on several GPCR including β2-adrenergic 
and chemoattractant receptors allowed formulating the 
pharmacological concept that Na+ acts like a universal 
allosteric modulator of GPCR (Seifert and Wenzel-Seifert 
2001). This pharmacological concept was confirmed by the 
recent studies showing crystal structures of GPCRs bound 
to Na+. The crystal structures show that the Na+ binds in an 
allosteric binding site near the highly conserved Asp2.50 
(Liu et al. 2012, Fenalti et al. 2014, Katritch et al. 2014, 
Miller-Gallacher et al. 2014). Based on the MD simulation 
data, it can be assumed that the monovalent cations bind 
to the allosteric site by coming from the extracellular side. 
When following the binding trajectory, the cations pass the 
orthosteric ligand binding site (Selent et al. 2010, Yuan et 
al. 2013, Wittmann et al. 2014).
The most detailed ideas about modulation of GPCRs by 
monovalent cations were recently presented by Strasser 
and others (2015). Based on crystal structures of the human 
histamine H1 receptor (Shimamura et al. 2011), human 
dopamine D3 receptor (Chien et al. 2010), human adenosine 
A2A receptor (Liu et al. 2012) and human δ-opioid receptor 
(Fenalti et al. 2014), these authors performed MD simulations 
of GPCR embedded in a lipid bilayer and surrounded by 
water molecules and ions with the aim to observe its 
conformational dynamics on a molecular level. These 
studies allowed delineating the binding pathways for ions 
and binding and unbinding of water molecules approaching 
GPCR from extracellular side of plasma membrane into an 
orthosteric and allosteric binding sites, respectively.
The calculation of interaction energy (ΔG) at an 
intersecting plane through the channel between the 
ortho- and allosteric binding site of human histamine H3 
receptor (hH3R) showed that there are two preferred areas 
for cations: first, around the highly conserved Asp3.32 in 
orthosteric site and second, around the highly conserved 
Asp2.50 in the allosteric binding site. With increasing 
size of the cation in the series Li+→Na+→K+→Rb+→Cs+, the 
energetically favoured area decreases. Additionally, in 
the same series, transition of the cation through the 
connecting channel becomes energetically more and more 
disfavoured.
Water molecules are important in interaction of a Na+ 
with the allosteric binding site (Liu et al. 2012, Katritch et 
al. 2014) and previous modeling studies showed that water 
molecules connect the orthosteric and the allosteric binding 
site (Wittmann et al. 2014). While the preferred binding area 
of the analyzed cations is very similar for the orthosteric 
binding site, there are obvious differences in the preferred 
binding for Li+ and Na+ on the one hand and K+, Rb+ and Cs+ 
on the other hand: while Li+ and Na+ bind deeper into the 
allosteric pocket, K+, Rb+ and Cs+ bind preferably at the 
area between the binding channel and the upper part of 
the allosteric binding site. Here, the hydration by water 
molecules or coordination by amino acid side chains and the 
preferred hydration number play a role. These differences 
lead to distinct signatures of cation binding in the allosteric 
site. Consequently, binding of different monovalent cations to 
the allosteric site may result in distinct interaction networks 
within the receptor, and these different interaction patterns 
may result in different receptor conformations.
Thus, in similarity with conventional GPCR ligands, 
GPCR-specific structure-activity relationships for various 
cations are emerging (Strasser et al. 2015). Based on these 
data, it can be suggested that there is a rising preference 
for binding of a monovalent cation in the Hofmeister (1888) 
series Cs+→Rb+→K+→Na+→Li+. This trend regarding the basal 
GTP hydrolysis was also shown previously by experimental 
studies of hH3R for K+→Na+→Li+ (Schnell and Seifert 2010).
Lithium dosing and toxicity
Lithium salts, mostly in the form of lithium carbonate 
(also acetate, citrate, gluconate or sulfate), are administered 
as an oral tablets [in daily dose 0.4 to 2.0 g/day of lithium 
carbonate depending on age and bodyweight (Oruch et al. 
2014)]. Following oral administration is lithium rapidly and 
completely absorbed from gastrointestinal tract (Suwalsky 
et al. 2007, Oruch et al. 2014). The effectiveness of lithium 
is dependent on dose and reliably correlates with serum 
concentration (Grandjean and Aubry 2009a). The typical 
therapeutic range in blood is 0.5 to 1.2 mM, however, the 
higher concentrations are needed for the treatment of acute 
mania (Grandjean and Aubry 2009a, Young 2009, Oruch et al. 
2014). The doses above 1.5 mM have to be regarded as toxic 
(Young 2009). Toxicity associated with lithium treatment 
is highly prevalent as 75 to 90% of patients have signs or 
symptoms of toxicity during their treatment (Mallinger 
et al. 1990, 1997, Webb et al. 2001, Gill et al. 2003). The 
occurrence of toxicity is related to the serum concentration 
of lithium. Mild toxicity appears at levels up to 2.5 mM, and 
life-threatening effect is manifested at levels above 3.5 mM 
(Peces and Pobes 2001, Borras Blasco et al. 2005); the patients 
with concentrations as high as 6 mM (Dupuis et al. 1996), 
and even 9.6 mM (Jaeger et al. 1993) lithium serum levels 
following acute intoxication were reported.
The overall concentration of lithium in the brain is 
only poorly correlated with serum concentration and 
brain/serum ratios based on 7Li magnetic resonance 
spectroscopy (7Li MRS) were determined in 0.4–1.0 range 
(Soares et al. 2000).
In addition to its proven effectiveness, however, lithium 
has particularly problematic side effects associated with a 
number of difficulties and risks. It has narrow therapeutic 
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window and overdosing is therefore a risky factor of proper 
therapy but even the correct dosage can lead to undesirable 
side effects (Can et al. 2014). Moreover, effect of lithium, 
especially when used as antidepressant, is evident after at 
about 2 months, which precludes its use when a fast-acting 
pharmacological treatment is necessary (Can et al. 2014). 
In the treatment of bipolar depression, the disadvantage of 
lithium is due to the delayed effect of 6–8 weeks, compared 
with 6–10 days in the treatment of acute mania (Gershon et 
al. 2009, Grandjean and Aubry 2009b).
Up-to-date review of mood stabilizers clinical 
management was performed last year by Murru and 
others (2015). According to this study mood stabilizers 
(including lithium) have different tolerability profiles and 
are eventually associated to cognitive, dermatological, 
endocrine, gastrointestinal, immunological, metabolic, 
nephrogenic, neurologic, sexual and teratogenic adverse 
effects. Long-term lithium treatment indicates a possibility 
of nephrotoxic effects of this ion (Rybakowski et al. 2012) 
and after many years of treatment renal impairment may 
occur. Moreover lithium is reabsorbed in the kidney after 
the glomerular filtration. It can be assumed that therapeutic 
outcome of lithium is related with the functional expression 
of sodium-phosphate cotransporter in the kidney which 
contributes to reabsorption of more than 65.9% (Uwai et al. 
2014). Lithium-induced renal toxicity is mainly manifested 
as a nephrogenic diabetes insipidus (NDI). NDI, which can 
be congenital or acquired (for example lithium therapy), 
results from failure of the kidney to respond to vasopressin 
(Sands et al. 2006). On the other hand long-term, low-
dose (0.2–0.4 mmol/l) lithium treatment does not impair 
renal function in the elderly (Aprahamian et al. 2014) 
and end-stage renal disease is a very rare complication. 
Long-term lithium treatment is except of a decline of 
renal function also associated with hyperthyroidism and 
hypercalcaemia (Shine et al. 2015). Common acute adverse 
effects of lithium as nausea, dysguesia, vomiting, loss of 
appetite or diarrhea are usually transient and manageable 
with dose reduction. Concerning dermatological problems 
the most common are acne and psoriasis. Mild cognitive 
symptoms are frequent with higher plasma levels of lithium 
but the real impact of therapeutic blood levels on cognitive 
impairments in bipolar disorder has not been clarified 
(López-Jaramillo et al. 2010). Treatment with lithium may 
induce weight gain and sexual dysfunction; the teratogenic 
risk is relatively low in absolute terms (Murru et al. 2015).
Lithium and membrane lipids; biophysical studies 
of direct interaction of ions with model lipid 
bilayers and natural membranes
The influence of physiologically relevant ions (Na+, 
K+, Cl−, Ca2+, and Mg2+) on model lipid membranes was 
extensively studied in the past (Böckmann et al. 2003, Vacha 
et al. 2009). Other ions, such as Li+, Cs+, NH4+, Ba2+, La3+, F−, Br−, 
I−, NO3−, and SCN−, were also investigated (McLaughlin et al. 
1978, Garcia-Celma et al. 2007), but, because the specificity 
of ionic effects were more pronounced for anions than 
for cations, the number of experimental data on analysis 
of cationic effects were sparser (Tatulian 1987, Clarke and 
Lupfert 1999, Kunz et al. 2004, Garcia-Celma et al. 2007). 
However, the conclusion drawn from all these studies was 
unequivocal: the strongest effects were observed for ions 
characterized by a high charge density: bivalent cations 
Mg2+, Ca2+ and Li+ (Pabst et al. 2007, General discussion 2013). 
Since some of naturally occurring lipids are anionic, 
adsorption of cations to natural lipid membranes is 
stronger than to electrically neutral model membranes. 
This is due to the coulombic attraction between positively 
charged cations and negatively charged head-groups in the 
inner leaflet of natural lipid bilayer. For example, in mixed 
POPC (1,2-palmitoyl-oleoyl-sn-glycero-3-phosphocholine)/
POPS (1,2-palmitoyl-oleoyl-sn-glycero-3-phosphoserine) 
(4:1, mol:mol) lipid bilayers, which are often used as a 
model of inner leaflet of a plasma membrane enriched in 
PS, adsorption of cations was found to follow the reversed 
Hofmeister series: Na+>K+>Cs+ (Eisenberg et al. 1979).
Most lipids exhibit similar chemical properties in the 
presence of alkali metal ions, with one exception – Li+. 
Interaction of lithium with phosphatidylserine (PS) bilayer, 
unlike interaction of other monovalent ions, leads to the 
isothermal crystallization and production of crystalline 
lipid complexes, Li+-PS (Hauser and Shipley 1981, 1983). PS 
is the main acidic, negatively charged phospholipid present 
in all eukaryotic biomembranes, it is preferentially localized 
in inner leaflet of plasma membrane and its content is 
especially high in neuronal membranes. Accordingly, the 
structure of model dipalmitoylphosphatidylserine (DPPS) 
bilayer was strongly altered by lithium addition: DPPS 
membrane was transferred from disordered to gel state 
and became more hydrated at lipid-water interface (Lopez 
Cascales and Garcia de la Torre 1997). Lithium exhibited 
the strong affinity for lipid phase and displaced the sodium 
ions towards the water space. Binding of Li+ and Na+ to DPPS 
was associated with dehydration of both ions. The decrease 
of water molecules in the first hydration shell of these ions 
was compensated by lipid oxygen’s.
Electrostatic interaction of lowconcentrations of Li+ 
(<1 mM) with polar head-group region of phosphatidylcholine 
located in the outer monolayer of the erythrocyte membrane 
was suggested to represent the primary factor inducing 
the pathological change of intact red blood cell into an 
“echynocytotic type” characterized by formation of blebs 
and protuberances on the cell surface (Suwalsky et al. 2007).
More recent publications using computer simulations 
showed that adsorption of Na+ to negatively charged 
membranes often leads to complexation of up to 4 lipid 
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molecules, but the exact binding sites were dependent 
on the force field (Pandit et al. 2003, Porasso and Lopez 
Cascales 2009, Broemstrup and Reuter 2010). Addition 
of 20 mol% of POPS to zwitterionic POPC strengthened 
the adsorption of monovalent ions to lipid bilayer with 
the order of: Na+>K+>Cs+ (Jurkiewicz et al. 2012). The 
time-resolved fluorescence solvent relaxation studies of 
interaction of sodium, potassium and cesium chlorides 
with POPC/POPS bilayer by Laurdan GP indicated the 
decrease of both mobility and hydration of lipid carbonyls. 
Molecular dynamics simulations were best interpreted as 
the deep penetration of ions down to the glycerol level 
of the lipid bilayer and pairing with oxygen atoms of 
carbonyl groups. Monovalent ions were found to bridge 
the neighboring lipids forming the clusters of up to 4 lipid 
molecules. This type of bridging decreased the average 
lipid area within the plain of membrane, thickened the 
membrane transversally, caused the rising of lipid head-
groups and hindered lipid dynamics. Importantly, all 
these effects were found to follow the same, Hofmeister 
ordering as the cationic adsorption to the bilayer: 
Na+>K+>Cs+ (Jurkiewicz et al. 2012).
Analysis of interaction of lithium, sodium, potassium 
and cesium with plasma membranes isolated from 
HEK293 cells by Laurdan GP indicated the low-affinity 
type of interaction only proceeding in the order: 
Li+>Na+>K+>Cs+ (Vosahlikova et al. 2014). The interaction 
of ions with negatively charged POPC/POPS and POPC/
POPS/cholesterol vesicles decreased in the same 
order: Li+>Na+>K+>Cs+ and was interpreted as decreased 
hydration and mobility of the polar head-group region of 
lipid bilayer. The same order of efficiency of monovalent 
cations in both types of membranes (HEK293 membranes 
and POPC/POPS vesicles), which was clearly related to 
the surface charge density of a given cation, represented 
a contribution to biophysical studies of specific ionic 
effects related to the early works of Franz Hofmeister 
(Hofmeister 1888). The so-called Hofmeister series of 
ions have been found to be similar for many different 
phenomena observed at complex macromolecular, 
polymeric and biological interfaces. However, at present 
time, there is a growing evidence for the complex 
origin of these effects (General discussion 2013) as an 
experimental systems have been identified in which the 
Hofmeister series can be partly or completely reversed 
(Parsons et al. 2010, Schwierz et al. 2010).
In this context, the role of counter anions has to be 
considered. The iodide anions (I−), being more hydrophobic 
than Cl− and Br−, were found to penetrate deeply into the 
membrane bilayer (Jurkiewicz et al. 2011). Importantly, 
iodide salts of monovalent cations were more efficient 
than chloride salts when modulating agonist binding and 
G protein coupling of β2-adrenergic, chemokine CXCR4 
and histamine H3 receptors (Seifert 2001, Kleemann et al. 
2008, Schnell and Seifert 2010). Data of Vosahlikova and 
others (2014) supported these results as the inhibition 
of agonist [3H]DADLE binding to δ-OR-Gi1α (C351I) fusion 
protein stably expressed in HEK293 cells was increased 
in the order: NaCl<NaBr<NaI (Fig. 2A). The same order of 
efficacy was found for inhibition of the basal and DADLE-
stimulated [35S]GTPγS binding by these salts (Fig. 2B).
Fig. 2. Decrease of [3H]DADLE (A) and [35S]GTPgS binding (B) by NaCl, 
NaBr, NaI (Fig. 4 in Vosahlikova et al. 2014). [3H]DADLE and [35S]GTPγS 
binding assays were performed in ion-free and 145 mM NaCl, NaBr and 
NaI containing media. P2 membrane fraction isolated from PTX-untreated 
HEK293 cells stably expressing δ-OR-Gi1α (C351I) fusion protein was used. 
Numbers represent the means ± SEM of 3 binding assays performed in 
triplicate. The same membrane preparation was used in all assays. Data 
were analyzed by one-way ANOVA followed by Bonferroni’s Multiple 
Comparison Test (ns, p>0.05; *, p<0.05; **, p<0.01; ***, p<0.001).
The effect of therapeutic concentrations of lithium 
on membrane lipids prepared from natural cells 
and tissues
Lopez-Corcuera, in his work from 1988 (Lopez-Corcuera 
et al. 1988), examined the effect of prolonged influence 
of therapeutic concentrations of lithium salts on lipid 
composition and biophysical properties of synaptosomal 
plasma membrane vesicles (SV) prepared from rat 
brain. Fluorescence polarization of lipophilic (DPH, 
1,6-difenyl-1,3,5-hexatriene) and charge-sensitive (ANS, 
1-anilinonaphthalene-8-sulfonic acid) probes was used to 
study membrane lipid structure. Steady-state polarization 
of DPH was significantly lower in SV prepared from lithium 
treated animals. Decrease of DPH polarization was due to 
the increase of S-order parameter. Lithium-treatment was 
also found to change fluorescence intensity of ANS bound 
to surface of SV and increase the content of unsaturated 
fatty acids in membrane phospholipids. The cholesterol-
phospholipid ratio was unchanged.
The effect of the long-term administration of different 
antidepressants on composition of rat brain lipids was studied 
in detailed manner by Fisar and others (2005). Significant 
decrease in content of PE (phosphatidylethanolamine) was 
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noticed after administration of maprotiline, citalopram 
and moclobemide. Membrane cholesterol level was 
decreased by desipramine but increased after citalopram 
and lithium. Electroneutral phospholipids were decreased 
after administration of all tested antidepressants with 
exception of desipramine. Decrease of PS was noticed 
after maprotiline and desipramine; phosphatidylinositol 
was decreased by lithium treatment. Statistically 
significant negative correlation between cholesterol 
and electroneutral phospholipids was clearly identified. 
Membrane microviscosity was only slightly decreased by 
desipramine and increased by citalopram.
Of the many hypotheses regarding the action of mood 
stabilizers in bipolar illness, “arachidonic acid (AA) cascade” 
hypothesis was reviewed in detailed manner (Rapoport et 
al. 2009). This hypothesis is based on evidence that chronic 
administration of lithium, carbamazepine, valproate or 
lamotrigine to rats down-regulated AA turnover in brain 
phospholipids and decreased formation of prostaglandin 
E2 and expression of AA-cascade enzymes – cytosolic 
phospholipase A2, cyclooxygenase-2 and/or acyl-CoA 
synthetase. The changes were selective for AA, since the 
brain metabolism of docosahexaenoic and palmitic acids 
was not unaffected. Topiramate, ineffective in bipolar 
illness, did not modify the rat brain AA cascade.
Down-regulation of the AA cascade by the mood stabilizers 
corresponded to inhibition of AA neurotransmission by 
dopaminergic D2-like and glutamatergic NMDA-receptors. 
Unlike the mood stabilizers, antidepressants that increase 
switching of bipolar depression to mania, up-regulated 
the rat brain AA cascade. These observations suggested 
that the brain AA cascade is a common target of mood 
stabilizers and bipolar symptoms, particularly in mania, 
are associated with an up-regulated AA cascade and excess 
AA signaling via D2-like and NMDA-receptors (Rapoport et 
al. 2009).
The thorough and comprehensive review of the role of 
brain n-3 polyunsaturated fatty acids (PUFA), glycerolipids, 
glycerophospholipids and sphingolipids in induction of 
the major depression and anxiety disorders was recently 
presented by Muller and others (2015). The authors conclude 
that large number of observational and interventional 
studies convincingly indicated the beneficial effects of 
n-3 long-chain PUFAs in the treatment of depression and 
anxiety. However, more research is needed to determine 
the most efficient type, dose and duration of n-3 PUFA 
supplementation; the most efficient treatment may be 
limited to specific subgroups of patients only. It should also 
be noted that from current mechanistic research it is not 
clear whether PUFA effects in depression and anxiety are 
mediated by changing the properties of plasma membrane 
itself or by altered levels of PUFA-derived lipid signaling 
molecules (Wilson and Nicoll 2002, Chevaleyre et al. 2006, 
Regehr et al. 2009).
CONCLUSIONS
Lithium is still the most effective therapy for depression. 
It “cures” a third of the patients with manic depression, 
improves the lives of about a third, and is ineffective in about 
a third. Anticonvulsants valproate, carbamapazine, and 
lamotrigene may be useful in patients that do not respond 
to lithium (Young 2009). Even though there is a decline in 
the use of lithium, it is still recommended as the first choice 
for dealing with bipolar disorder according to all of the 
current medical handbooks (Grandjean and Aubry 2009b). 
Lithium is a typical mood stabilizer and has in this group 
of drugs a unique position. It has both the antimanic and 
extraordinary antidepressant activity; the antimanic effect 
being more pronounced than antidepressant. Unlike mood 
stabilizers that were originally indicated in the treatment 
of other diseases (anticonvulsants for treating epilepsy and 
antidepressants to treat schizophrenia), lithium is almost 
entirely effective in the treatment of mood disorders 
(Can et al. 2014). Moreover, there is evidence that lithium 
reduces the high risk of suicide in patients with bipolar 
disorder (Grandjean and Aubry 2009b, Kovacsics et al. 2009, 
Manchia et al. 2013). 
The effective dose range for lithium is 0.6–1.0 mM in 
serum and >1.5 mM may be toxic. Serum lithium levels 
of 1.5–2.0 mM have mild and reversible toxic effects on 
kidney, liver, heart, and glands. Serum levels of >2 mM 
may be associated with neurological symptoms, including 
cerebellar dysfunction. Prolonged lithium intoxication 
>2 mM can cause permanent brain damage (Young 2009).
Although the concentrations at which Li+ affects GPCR 
function in vitro are much higher than the therapeutic 
plasma concentrations in patients (≈1 mM), it cannot be 
excluded that Li+ interacts with GPCRs in vivo. Limitation 
of the studies conducted with the effect of Li+ on GPCRs 
in vitro was the fact that Li+ was studied alone and not in 
competition with Na+ or K+ (Gierschik et al. 1991, Seifert 
2001). In similarity with conventional GPCR ligands, 
GPCR-specific structure-activity relationships for various 
cations are emerging at present time (Strasser et al. 2015). 
It can be suggested that there is a rising preference for 
binding of a monovalent cation in the so-called Hofmeister 
(1888) series Cs+→Rb+→K+→Na+→Li+. This trend regarding the 
basal level of GTP hydrolysis by G proteins was also shown 
in studies of hH3R: K+→Na+→Li+ (Schnell and Seifert 2010).
As recently reviewed by Can and others (2014), the first 
usage of lithium was in the form of bromide salt: “Latterly 
I have used the bromide of lithium in cases of acute mania 
and have more reason to be satisfied with it than with any 
other medicine calculated to diminish the amount of blood 
in the cerebral vessels, and to calm any nervous excitement 
that may be present. The rapidity with which its effects are 
produced renders it specially applicable in such cases. The 
doses should be large – as high as sixty grains even more 
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– and should be repeated every two or three hours till be 
produced, or at least till half a dozen doses be taken. After 
patient has once come under its influence, the remedy 
should be continued in smaller doses, taken three or four 
times in the day” (Hammond 1871, p. 381).
This clinical report, formulated 144 years ago, is 
compatible with the observations indicating that bromide 
(Br−) and iodide (I−) anions, being more hydrophobic than 
Cl−, were found to penetrate deeply into the membrane 
bilayer (Jurkiewicz et al. 2011). Importantly, iodide salts of 
monovalent cations were more efficient than chloride salts 
when modulating agonist binding and G protein coupling of 
β2-adrenergic, chemokine CXCR4 and histamine H3 receptors 
(Seifert 2001, Kleemann et al. 2008, Schnell and Seifert 2010). 
Data of Vosahlikova and others (2014) supported these results 
as the inhibition of agonist [3H]DADLE binding to δ-OR-Gi1α 
(C351I) stably expressed in HEK293 cells was increased in the 
order: NaCl<NaBr<NaI (Fig. 2A). The same order of efficacy 
was found for inhibition of the basal and DADLE-stimulated 
[35S]GTPγS binding by these salts (Fig. 2B).
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